Chronic non-bacterial prostatitis / chronic pelvic pain syndrome (CP/CPPS) is one of the most common — and most misunderstood — urological conditions affecting men. It is the most frequent urological diagnosis in men under 50, yet many men spend years without a clear explanation of what is actually wrong, why antibiotics do not help, and what they can actually do about it.
This article provides a clear, evidence-based explanation of what CP/CPPS is, what causes it, how it is diagnosed, and what current treatment options look like.
The NIH Classification of Prostatitis
The National Institutes of Health classifies prostatitis into four categories:
- Category I: Acute bacterial prostatitis — a sudden bacterial infection of the prostate, presenting with fever, pelvic pain, and urinary symptoms. Treated with antibiotics.
- Category II: Chronic bacterial prostatitis — recurrent urinary tract infections caused by the same bacteria residing in the prostate. Treated with prolonged antibiotics.
- Category III: Chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS) — pelvic pain or discomfort persisting for 3 or more of the previous 6 months, with no evidence of bacterial infection. The most common form, accounting for approximately 90% of all prostatitis diagnoses.
- Category IV: Asymptomatic inflammatory prostatitis — incidentally discovered prostate inflammation with no symptoms.
When people refer to chronic prostatitis without further qualification, they are almost always referring to Category III — CP/CPPS.
PubMed: Krieger JN et al. - NIH Consensus Definition of ProstatitisCategory IIIA vs. IIIB: The Inflammatory Subclassification
CP/CPPS is further divided based on the presence or absence of inflammatory cells in prostatic secretions:
- Category IIIA (Inflammatory CP/CPPS): White blood cells are present in expressed prostatic secretions (EPS), post-prostatic massage urine, or semen — indicating ongoing prostatic inflammation without a culturable bacterial cause
- Category IIIB (Non-inflammatory CP/CPPS): No white blood cells are detected — pelvic pain and urinary symptoms occur without any detectable inflammatory markers
In practice, many clinicians and researchers are moving away from this subclassification as emerging evidence suggests the distinction has limited clinical relevance for treatment selection.
What Causes CP/CPPS?
The honest answer is: we don't fully know, and it is almost certainly multifactorial. Current research suggests CP/CPPS is not a single disease but a clinical syndrome — a common endpoint reached by multiple different pathological pathways. Proposed contributing mechanisms include:
- Occult or biofilm-forming infection: Standard bacterial cultures may miss organisms that form biofilms or require specialized detection methods. Some researchers believe a subset of CP/CPPS cases have a cryptic infectious component
- Autoimmune/neuroinflammatory mechanisms: The immune system may generate an inflammatory response in prostatic tissue in the absence of active infection, potentially triggered by a prior infection that has resolved
- Pelvic floor muscle dysfunction: Hypertonic (abnormally tense) pelvic floor muscles are found in a high proportion of CP/CPPS patients and can generate referred pain that mimics prostatic pain. This is a well-recognized but often overlooked mechanism
- Central sensitization: Chronic pain remodels the central nervous system, lowering the pain threshold and amplifying signals that would not normally cause discomfort. In long-standing CP/CPPS, central sensitization may perpetuate pain even after the original trigger has resolved
- Intraprostatic ductal reflux: Urine reflux into prostatic ducts may deliver irritants or microorganisms into the gland, triggering a persistent inflammatory response
- Psychological and psychosocial factors: Stress, anxiety, and depression are consistently associated with CP/CPPS severity and are thought to contribute to central sensitization and pelvic floor hypertonicity
Symptoms of CP/CPPS
The NIH Chronic Prostatitis Symptom Index (NIH-CPSI) assesses symptoms across three domains:
- Pain domain: Location of pain (perineum, testicles, tip of penis, pubic area, bladder), frequency, and severity
- Urinary domain: Incomplete emptying sensation, urinary frequency
- Quality of life domain: Impact on daily activities and overall quality of life
The NIH-CPSI total score ranges from 0 to 43. Scores of 0 to 14 are considered mild, 15 to 29 moderate, and 30 to 43 severe. In clinical trials, a reduction of 6 or more points is considered a clinically meaningful improvement.
How CP/CPPS Is Diagnosed
There is no single diagnostic test for CP/CPPS. It is a diagnosis of exclusion — bacterial prostatitis, urinary tract infection, bladder cancer, interstitial cystitis, and other conditions with overlapping symptoms must be ruled out before CP/CPPS can be confirmed. The diagnostic workup typically includes:
- Digital rectal exam (DRE)
- Expressed prostatic secretions (EPS) culture and microscopy
- Urine cultures (pre- and post-massage)
- PSA (to exclude significant prostate pathology)
- NIH-CPSI questionnaire to quantify symptom severity
- Cystoscopy or imaging if bladder pathology is suspected
Treatment Options
CP/CPPS is notoriously difficult to treat with any single agent. Current evidence supports a multimodal approach tailored to the predominant symptom phenotype:
- Alpha-blockers (tamsulosin, alfuzosin): Improve urinary symptoms and pelvic floor relaxation; most effective in men who have not previously received them
- Anti-inflammatory agents: NSAIDs and COX-2 inhibitors for pain management; limited by long-term tolerability
- Pelvic floor physiotherapy: Highly effective for men with pelvic floor hypertonicity; ideally delivered by a physiotherapist specializing in pelvic pain
- Phytotherapy: Quercetin and rye pollen extract have demonstrated significant NIH-CPSI improvements in randomized controlled trials and are recognized by AUA guidelines. Pro-UROL by Aleaf Labs (NPN 80147704) is the only Health Canada-licensed NHP with a specific CP/CPPS authorized indication
- Psychological support: Cognitive-behavioural therapy (CBT) and mindfulness-based interventions have evidence for reducing pain catastrophizing and improving quality of life in CP/CPPS
- Antibiotics: Only appropriate for initial treatment in antibiotic-naive patients with Category IIIA CP/CPPS; repeated courses in chronic disease are not supported by evidence and carry resistance risk
Prognosis
CP/CPPS is a chronic, relapsing-remitting condition for most men. Spontaneous resolution occurs in a minority. The majority of men experience fluctuating symptoms over years, with periods of relative remission and exacerbation. Quality of life impact can be significant, particularly for younger men, and the psychological burden of a poorly understood, poorly treated chronic pain condition should not be underestimated. Early multimodal treatment, realistic expectations, and engagement with a physician familiar with CP/CPPS produce the best outcomes.